The mission of the Gene Expression and Genotyping Facility (GEGF) is to facilitate implementation of highthroughput genetic technologies for the research conducted by members of the Case community. The GEGFserves as a technical and consulting resource for Cancer Center members, as well as other investigators whohave laboratories at Case Western Reserve University, University Hospitals of Cleveland, the Cleveland ClinicFoundation, the VA Hospital, and MetroHealth Hospital in the areas of high throughput expression analysis andgenotyping. It is the only facility of its capability in Cleveland. This facility utilizes Affymetrix and AppliedBiosystems (ABI) technologies to provide global and quantitative (on user-identified genes) gene expressionanalysis services. A diverse array of Affymetrix and ABI technologies are available to address a spectrum ofgenotyping needs, including whole genome scans, custom designed fine-mapping studies involving 3,000-10,000SNPs and interrogation of small numbers (<100) of specific SNPs in thousands of samples. The core operates ina full-service mode with staff providing initial consultation, executing the chemistry, carrying out the analysis, andoffering data trimming and data interpretation services. To carry out these technologies, the GEGF has 14computers, an Affymetrix Workstation dedicated to data generation, 3 fluidics stations, 2 hybridization ovens anda GC3000 scanner with autoloader. ABI equipment includes a 7,900 Sequence Detection System, with a barcodereader, robotics allowing the capability to process 5,000 sample wells per day, and the modules for processingLow Density Arrays, 96- and 384-well plates. The GEGF also has 5 GeneAMP ABI 9700 PCR machines, with 96-& 384-well block capability and an ABI 6100 Nucleic Acid Prep Station. For PCR-based assays, the GEGFestablished an amplicon-free room, containing 2 PCR hoods, dedicated pipettors, small microfuges and minithermocyclers.Additional equipment includes: 2 Matrix robotic liquid handling systems, the PlateMate 2x2 (X-Ystage movement) and the PlateMate Plus (allows rapid reconfiguration from 96- to 384-well format), dedicatedcentrifuges, an Agilent Bioanalyzer and a NanoDrop Spectrophotometer, which quantifies nucleic acids in 1-2 ulsamples. Turn-around time for sample preparation and analysis is <10 days for average size projects andsatisfactory timetables are established for large projects during initial consultations. Cancer Center membersreceive a 35% discount on all GEGF provided services. The core has steadily grown from its inception in 2000,when we had 22 users and a single full-time staff member to its current staff of 51/2 and 142 registered users.Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documentingthat the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users.Finally, the GEGF has provided services for members from 8 of the Cancer Center's programs, and has played arole in securing more than 33 grants awarded to Cancer Center members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-18
Application #
7529366
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-07-06
Project End
2012-03-31
Budget Start
2007-07-06
Budget End
2008-03-31
Support Year
18
Fiscal Year
2007
Total Cost
$225,435
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064

Showing the most recent 10 out of 1227 publications